Novavax, Inc.
A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).
Item 4 is hereby amended to add the following: On May 14, 2026, the Reporting Persons sent a presentation (the "Elevating Novavax Presentation") to the board of directors of the Issuer (the "Board") outlining what they believe to be the failures of the current leadership, specifically noting the following: (i) marketing failure since 2023; (ii) underwhelming Sanofi partnership; (iii) capital market mismanagement; and (iv) leadership enriching itself instead of building value. The foregoing description of the Elevating Novavax Presentation does not purport to be complete and is qualified in its entirety to the Elevating Novavax Presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 4 is hereby amended to add the following: On May 14, 2026, the Reporting Persons sent a presentation (the "Elevating Novavax Presentation") to the board of directors of the Issuer (the "Board") outlining what they believe to be the failures of the current leadership, specifically noting the following: (i) marketing failure since 2023; (ii) underwhelming Sanofi partnership; (iii) capital market mismanagement; and (iv) leadership enriching itself instead of building value. The foregoing description of the Elevating Novavax Presentation does not purport to be complete and is qualified in its entirety to the Elevating Novavax Presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 4 is hereby amended to add the following: On May 14, 2026, the Reporting Persons sent a presentation (the "Elevating Novavax Presentation") to the board of directors of the Issuer (the "Board") outlining what they believe to be the failures of the current leadership, specifically noting the following: (i) marketing failure since 2023; (ii) underwhelming Sanofi partnership; (iii) capital market mismanagement; and (iv) leadership enriching itself instead of building value. The foregoing description of the Elevating Novavax Presentation does not purport to be complete and is qualified in its entirety to the Elevating Novavax Presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| STATE STREET CORPORATION | 13GPassive | 7.1% | 11.74M | Aug 7, 2026 |
| Himanshu H. Shah | 13D/AActivist | 9.03% | 14.84M | May 15, 2026 |
Item 4 is hereby amended to add the following: On May 14, 2026, the Reporting Persons sent a presentation (the "Elevating Novavax Presentation") to the board of directors of the Issuer (the "Board") outlining what they believe to be the failures of the current leadership, specifically noting the following: (i) marketing failure since 2023; (ii) underwhelming Sanofi partnership; (iii) capital market mismanagement; and (iv) leadership enriching itself instead of building value. The foregoing description of the Elevating Novavax Presentation does not purport to be complete and is qualified in its entirety to the Elevating Novavax Presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | ||||
| Shah Capital Management | 13D/AActivist | 8.95% | 14.71M | May 15, 2026 |
Item 4 is hereby amended to add the following: On May 14, 2026, the Reporting Persons sent a presentation (the "Elevating Novavax Presentation") to the board of directors of the Issuer (the "Board") outlining what they believe to be the failures of the current leadership, specifically noting the following: (i) marketing failure since 2023; (ii) underwhelming Sanofi partnership; (iii) capital market mismanagement; and (iv) leadership enriching itself instead of building value. The foregoing description of the Elevating Novavax Presentation does not purport to be complete and is qualified in its entirety to the Elevating Novavax Presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | ||||
| Shah Capital Opportunity Fund LP | 13D/AActivist | 8.51% | 14.00M | May 15, 2026 |
Item 4 is hereby amended to add the following: On May 14, 2026, the Reporting Persons sent a presentation (the "Elevating Novavax Presentation") to the board of directors of the Issuer (the "Board") outlining what they believe to be the failures of the current leadership, specifically noting the following: (i) marketing failure since 2023; (ii) underwhelming Sanofi partnership; (iii) capital market mismanagement; and (iv) leadership enriching itself instead of building value. The foregoing description of the Elevating Novavax Presentation does not purport to be complete and is qualified in its entirety to the Elevating Novavax Presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | ||||
| Vanguard Capital Management | 13GPassive | 5.09% | 8.31M | Apr 30, 2026 |
| BANK OF AMERICA CORP /DE/ | 13G/APassive | 4.1% | 6.66M | Apr 27, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| BlackRock, Inc. | 13G/APassive | 8.4% | 13.45M | Feb 5, 2025 |